Research Interests:
HIV biology and antiretroviral therapy; basic and clinical pharmacology of HIV protease inhibitors

Selected Publications:
Speck RR, Yu X-F, Hildreth JE, and Flexner C (2002) Differential effects of P-glycoprotein and multidrug resistance protein-1 on productive HIV Infection. J Infect Dis 186: 332-340.

Washington CB, Flexner C, Sheiner LB, Rosenkranz SL, Segal Y, Aberg JA, Blaschke TF; AIDS Clinical Trials Group Protocol (ACTG 378) Study Team. (2003) Effect of simultaneous versus staggered dosing on pharmacokinetic interactions of protease inhibitors. Clin Pharmacol Ther 73: 406-16.

Hamzeh FM, Benson C, Gerber J, Currier J, McCrea J, Deutsch P, Ruan P, Wu H, Lee J, Flexner C; AIDS Clinical Trials Group 365 Study Team. (2003) Steady-state pharmacokinetic interaction of modified-dose indinavir and rifabutin. Clin Pharmacol Ther. 73: 159-69.

Rufo P, Lin PW, Andrade A, Jiang L, Rameh L, Flexner C, Alper SL, Lencer WI (2004) Diarrhea-associated HIV-1 aspartyl protease-inhibitors potentiate muscarinic activation of Cl- secretion by T84 cells via prolongation of cytosolic Ca2+ signaling. Am J Physiol Cell Physiol 286: 998-1008.

Nettles RE, Kieffer TL, Parsons T, Johnson J, Cofrancesco J, Gallant JE, , Carson K, Siliciano RF, Flexner C. (2006)  Marked intraindividual variability in antiretroviral concentrations may limit the utility of therapeutic drug monitoring. Clin Infect Dis 42: 1189-1196.

De Gruttola V, Flexner C, Schapiro J, Hughes M, van der Laan M, Kuritzkes D.  Drug development strategies for salvage therapy: conflicts and solutions.  AIDS Res Hum Retroviruses 22:1106-9.

Return to Faculty Home